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1. Introduction 
Cryopreserved heart and vascular allografts are major prostheses of choice in cardiac 
surgery today, used in variety of treatment situations. Right and left ventricular outflow 
tract reconstruction in congenital heart diseases, cases of infective endocarditis, mitral valve 
plasty, and aortic aneurysm of infective etiology are the major indications for allograft use. 
Saphenous vein grafts with small-sized valves have also been reported to be beneficial in 
particular cases in reconstructing the right ventricular flow to the pulmonary artery for 
neonates and infants, since these valved vein grafts offer good performance in preserving 
right ventricular function in small children, thus leading to better clinical outcomes 
[Murakami, 2002; Tam, 2001].  
It has been over 40 years since the first heart valve allograft was performed by Dr. Ross for a 
case of congenital heart defect [Ross and Somerville, 1966]. Since then, heart valve allografts 
have entered into clinical use steadily, starting with the use of fresh grafts. Emerging 
techniques of cryopreservation, including programmed freezing methods and innovation of 
cryoprotective agents, have enabled long-term graft storage without the loss of morphological 
and biological benefits, and banking systems have made elective use possible. Tissue 
Banking system was introduced into Japan in 1997, and gradually became established as the 
method of choice mainly for congenital heart defects and infective cardiovascular diseases. 
The University of Tokyo Tissue Bank (UTTB) houses one of the biggest banks in Japan 
where related clinical investigations and scientific research is also conducted.  
In this chapter we describe the allograft processing, the characteristics, and the clinical 
results of cryopreserved aortic valve allograft that were shipped from UTTB. 
2. Tissue processing 
2.1 Procurement 
The tissues are usually collected in the operating theatre under sterile conditions, in the 
same manner as in an ordinary surgical procedure. Informed consent is obtained from the 
donor family in advance by the tissue bank donor coordinators. The procurement team 
consists of 4-6 surgeons, including cardiovascular surgeons for heart valve procurement and 
liver transplantation surgeons for venous graft procurement. A small piece of each allograft 
or adjacent connective tissue is sent for a culture test to rule out any contamination with 
www.intechopen.com
 
Aortic Valve Surgery 
 
124 
microorganisms. A blood specimen of the donor is also obtained in advance or during the 
procurement for serological study. Following a median sternotomy, the whole heart is 
excised and the heart valves and superior caval vein are dissected on a side table in the 
theatre. The descending thoracic aorta, inferior caval vein, and portal vein system, and veins 
from the lower extremities are also retrieved accordingly. Care is taken to process the tissues 
obtained from the thoracic cavity, the abdominal cavity, and the femoral region separately 
to avoid cross-contamination. The dissected tissues are immersed in disinfection medium: 
RPMI 1640 medium + l-glutamate (GIBCO, Invitrogen Corp., Grand Island, NY, USA) 
containing cefmetazole (240 μg/ml), lincomycin (120 μg/ml), and vancomycin (50 μg/ml), 
and polymyxin B (1000 μg/ml). Tissues from the thoracic cavity, abdominal cavity, and 
lower extremities are separately incubated in this antibiotic solution for 24 to 48 hours at 
4°C. Up to December 2000, amphotericin B (5 μg/ml) was added to the disinfection medium 
at the University of Tokyo Tissue Bank, since at the time the trachea was also recovered 
from the donor, which was considered to be contaminated with yeast.  
2.2 Trimming 
After immersion in the antibiotic solution, tissues are trimmed to an appropriate size and 
shape in a laminar flow cabinet (Figure 1 a,b). A surgeon performs the tissue dissection 
dressed in a sterile disposable operating theatre gown.  Tissues are packed in double-sterile 
bags (Figures 2a to 2d). Samples for microbiological testing are also taken from each graft at 
this time. Sediments obtained from filtration of the disinfection solution are also sent for 
microbiological testing. The tissues that are positive for microbes at trimming are excluded 
from clinical use.  
2.3 Cryopreservation 
The tissues are cryopreserved in RPMI 1640 containing 10% dimethyl sulfoxide (Me2SO) in a 
final volume of 100 ml, including the tissue graft. The doubly packed tissues are cooled at a 
rate of -1°C/min down to -40°C, and then at a rate of -5°C/min to -80°C, using a 
programmable freezer (Profreeze, Nippon Freezer Co., Ltd, Tokyo, Japan). The grafts are 
then stored in vapor-phase liquid nitrogen at -180°C until used. Ketheesan et al 
demonstrated that a freezing rate of -1°C/min best maintained the viability of cells 
[Ketheesan et al, 1996], and this is the standard method of cryopreservation regimen today. 
As for the duration of graft storage, we keep the grafts for a maximum of 5 years, because of 
possible damage to the packages.  
2.4 Thawing and clinical use 
Grafts are rapidly thawed in a 37°C sterile saline bath and rinsed by sequential dilution 
using 1000 ml lactate Ringer solution (Lactec G®) to completely remove Me2SO, because 
Me2SO can cause tissue damage at normal body temperature. A small piece of thawed tissue 
is submitted for microbiological and pathological tests for the final check of quality control 
of the graft.  
3. Characteristics of the heart valve allografts 
3.1 Immunogenicity 
In the past 40 years heart valve allografting, cryopreservation techniques (programmed 
freezing methods, innovation of cryoprotective agent, etc.) have improved significantly, and 
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                                     (a)                                                                                (b) 
Fig. 1. (a) Tissues trimming is performed in a laminar flow chart; (b) Muscle skirt is trimed 
to 4mm thick and 20mm long 
 
     
                                          (a)                                                          (b) 
 
                                       (c)                                                                            (d) 
Fig. 2. (a) Allograft after trimming; (b) The graft is immersed in medium containing 
cryoprotectant (first package); (c) First and second packages are sealed tight with a heat 
sealer; (d) Final view of the package 
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progress in techniques and establishment of tissue banking systems have enabled long-term 
graft storage. With more frequent use of allografts, questions related to the extent of the 
allografts’ antigenicity and the influence of the cryopreservation method on immunogenicity 
of the allografts has become a matter of discussion [Hoekstra et al., 1996].  
Results of clinical investigations and animal experimentation have shown that both fresh 
and cryopreserved valve allografts have a certain, albeit, low degree of immunogenicity. 
Such studies date back back to the 1990s and continue up to the present. Fischlein et.al. 
reported that allograft valves caused immunological reaction after implantation by 
monitoring the circulation mononuclear cell in the recipients’ peripheral blood; the 
immunological reaction was reversible without immunosuppressive treatment [Fischlein, 
1995]. The authors concluded that aortic valve allografts were able to induce an immune 
response in the recipient that was related to early graft destruction and failure. In further 
studies using a rat transplantation model, it appeared that cryopreservation diminished but 
did not eliminate the immunogenicity of the allograft [Oei, 2001]. O’Brien et al presented 
data showing a donor-specific immune response after aortic valve allografting in the rat 
[Zhao, 1994],  also confirmed in a clinical study [Hogan et al, 1996]. Graft rejection was also 
observed in infant cases receiving heart valve allografts [Rajani et al, 1998]. In several 
studies, mixed lymphocyte reaction (MLR) results showed recipient alloreactivity in rats 
[Rajani et al, 1998; Ketheesan et al, 1996; Oei et al, 2001; Saito et al, 2006]. The impact of 
cryopreservation manipulation on the alteration in the graft’s allogenicity is still under 
investigation, and it is worth noting that two previous studies [Ketheesan et al, 1996; Oei et 
al, 2001] have concluded that cryopreservation decreases the immunogenicity of allografts. 
However, our analyses have shown that there was no difference in immunogenicity before 
and after cryopreservation [Saito et al, 2006]. This discrepancy in the results may arise from 
the difference in the conduits used (valved conduits vs non-valved aortic grafts), or the 
experimental methodology, or may be related to the method of measurement, i.e., whether 
antigen non-specific T cell response induced by concanavalin A stimulation was used 
[Ketheesan et al, 1996; Oei et al, 2001], or antigen-specific T cell response to donor antigen 
was employed using a third alloantigen [Saito et al, 2006].  
Histological investigation was the major method of estimating the allogenicity of the 
cryopreserved allografts compared with fresh grafts [Legare et al, 2000; Moustapha et al, 
1997; O'Brien et al, 1987; Oei et al, 2002], and our experimental results also added some data 
on the alteration of allogenicity in cryopreserved tissues from a molecular perspective [Saito 
et al, 2006]. Consistent with the results of T cell responses, our investigation of graft revealed 
that cryopreservation did not modify the graft’s immunogenicity. Real-time PCR studies 
showed that the gene expression of TNFα, IFNγ, and iNOS (as a downstream effector of 
IFNγ pathway) in response to cryopreservation. In other words, cryopreservation did not 
modify graft allogenicity. Consistent with our results, Solanes et al recently reported that the 
cryopreservation method maintained immunogenicity of porcine arterial allografts [Solanes 
et al, 2005].  
Cellular viability of grafts is important in that it preserves the long term viability of grafts 
[O'Brien et al, 1987], and numerous studies have addressed the status of endothelial cell 
viability in cryopreserved heart valves and vascular allografts [Oei et al, 2002]. The 
importance of preserving endothelial cell viability after cryopreservation is a matter of 
controversy, since there are two opposite interpretations; one being that graft endothelial 
cell viability is decreased after cryopreservation and also after transplantation because of 
depletion of donor cellular population [Armiger,1995; Mitchell et al, 1995; Neves et al, 1997; 
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Niwaya et al, 1995; O'Brien et al,1987; Redwood and Tennant, 2001], and the other that graft 
cell viability is maintained to a certain degree even after cryopreservation, from 
morphological, metabolic, and chromosomal perspectives [Fischlein et al, 1995; Lang et al, 
1994; Oei et al, 2001].  Duration of warm ischemic time (i.e., the period from cardiac arrest of 
the donor and retrieval of the heart valve tissues to insertion in medium with antibiotic 
cocktail at 4°C), differences in the graft preparation method, and the antibiotic treatment 
regimen, may influence the outcome. In our animal experiments [Saito et al, 2006], eNOS 
gene expression level was measured in fresh and cryopreserved aortic allografts, which 
were processed in the same manner, including warm ischemic time and antibiotic treatment 
for a precise comparison. Levels of eNOS gene expression were similar in fresh and 
cryopreserved grafts, suggesting that endothelial cell viability is well-preserved at the 
molecular level after cryopreservation at the molecular level. Endothelial cells are also 
recognized as MHC class II antigen-presenting cells and may induce T-cell mediated 
immune responses after allotransplantation [Fischlein et al, 1995; Le Bas-Bernardet et al, 
2004; Mitchell and Lichtman, 2004; Ono et al, 1998].  
3.2 Resistance against infection 
Invasive infective endocarditis of the aortic root is a critical and challenging post-operative 
complication that needs to be treated, especially when it forms an abscess at the 
juxtavalvular structure that can perforate to other neighboring cardiac structures. Short-
term mortality rates due to this complication are reported to be 5% to 39% [Anguera et al, 
2006; Cabell et al, 2005; Chu, 2004; Hasbun, 2003; Motomura et al, 2002; Kilian et al, 2010; 
Perrotta et al, 2010]. Gram positive cocci such as Staphylococcus aureus are frequently 
isolated, and among these Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is 
associated with significantly higher mortality rates than other infections. Surgical treatment 
at the appropriate time is crucial, including complete resection of the infected area and 
substitution of the defect with valvular prostheses. The choice of valve prosthesis is a key 
issues for a better prognosis. As regards the choice of substitutes, a heart valve allograft is 
considered superior to the other prosthesis like mechanical valves and bioprosthetic valves. 
Since the 1990s, several retrospective studies have shown that possible superiority of the 
valve allograft use for severe infective endocarditis and prosthetic valve endocarditis cases 
from the clinical results [Grinda et al, 2005; Haydock et al, 1992; Leyh et al, 2004; Sabik et al, 
2002; Vogt et al, 1997; Yankah et al, 2005] ; however, there is no final consensus of an 
allografts’ potential of antimicrobial capacity due to the absence of randomized controlled 
studies and scientific evidence supporting this mechanism [Eichinger et al, 2002; Rowe et al, 
1999], and the presence of opposing opinions [El-Hamamsy et al, 2010; Klieverik et al, 2009]. 
Further information was contributed in 2008 by our group to strongly support the allografts’ 
property to overcome infection from a scientific point of view; the key substance conferring 
the antibacterial property was found to be indoleamine 2,3-dioxygenase (IDO) [Narui et al, 
2009; Saito et al, 2008]. 
IDO is a IFN-γ induced, rate-limiting enzyme of the L-tryptophan (Trp) -L-kynurenine 
(Kyn) pathway [Mellor and Munn, 2004; Munn et al, 1998]. IDO is an important factor in 
induction of immunological tolerance by suppressing T cell proliferation through Trp 
degradation, and by producing toxic Trp metabolites that have anti-bacterial properties 
[Bauer et al, 2005; Bozza 2005; Silva 2002]. A possible mechanism linking antimicrobial 
activity and possible immune tolerance of allografts is the contribution of IDO. Our study 
was based on an aortic transplantation model using inbred rats. Aortic allografts, isografts, 
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and control grafts were analyzed to determine the extent of IFNγ, TNFα, and IDO gene 
expression by quantitative RT-PCR. Also, Trp metabolite production in the graft was 
measured by liquid chromatography/tandem mass spectrometry analysis. The 
bacteriostatic effect of each graft and Trp metabolite production was determined by a MRSA 
proliferation assay. These experiments showed significant gene expression of IFNγ, TNFα, 
and IDO in the allografts but not in the isografts and MRSA growth was suppressed when 
incubated with allografts but not with isografts (Figure 3A). Among Trp metabolites, the 
bacteriostatic effect against MRSA was remarkable with 3-hydroxykynurenine (3-HK) 
(Figure 3B), and 3-HK was actually isolated from allografts but not from the isografts. It may 
be concluded that the allograft anti-infection property arises as a consequence of the 
biological reaction following allotransplantation, which is not expected to occur with  
 
 
 
Fig. 3. A) Antimicrobial activity of the allografts against MRSA growth in vitro. MRSA 
proliferated remarkably when cultured with control grafts, whereas allografts showed 
MRSA growth suppression. B) MRSA proliferation was visualized on the mannitol salt agar. 
(Saito et al., 2008) 
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artificial biomaterial or mechanical prosthesis. Because of this, the allograft heart valve will 
still be a prime material of choice in surgical procedures related to infective endocarditis.  
3.3 Allograft calcification 
Although durability of allografts is generally as good as that of bioprosthetic valves, they 
tend to fail sooner in young recipients, especially neonates and infants than in adults, 
because of progressive calcification and degeneration [Baskett et al, 1996; O'Brien et al, 
2001]. The precise mechanism regarding allograft calcification especially in the younger 
patients is still not fully understood; however, some studies have been reported [Mennander 
et al, 1991; Religa et al, 2003; Shioi et al, 2002; Tintut et al, 2000].  
Factors related to calcium metabolism in the young (e.g., hyperphosphatemia) are thought 
to be a possible mechanism promoting allograft calcification. Graft calcification in young 
rats was inhibited by restriction of dietary inorganic phosphate (Pi) or by blocking of Pi 
transport via the sodium-phosphate cotransporter by phosphonoformic acid (unpublished 
data).  
 
 
Fig. 4. MRSA Growth Curves with or without Tryptophan Metabolites at Various 
Concetrations (Narui et al., 2009) 
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4. Clinical experience from UTTB case series 
Heart valve allografts have proven to be useful in the management of aortic valve and aortic 
root pathology. It has been more than 40 years since an aortic valve allograft was first 
inserted. Although they are not the only device available for valve replacement, they provide 
superior clinical outcome compared with the other types of devices such as prosthetic valves 
(mechanical and bioprosthetic valves) when they are used for infective endocarditis. The 
purpose of this section is to present the clinical performance of cryopreserved aortic valve 
allografts, which were provided by the University of Tokyo Tissue Bank (UTTB).  
4.1 Patients and methods 
Between December 1998 and September 2010, 60 aortic valve allografts were provided from 
UTTB for aortic root reconstruction. All the patients’ characteristics were evaluated 
preoperatively (age, gender, indication for allograft transplantation and aortic allografts’) 
profiles, and short- and long-term outcomes were analyzed. Recipients and the allografts 
were matched by size; blood-type or gender match were not mandatory. Follow-up data 
including the survival, performance status, graft function, and cause of deaths or graft loss 
were collected by follow-up with the surgeons in charge at 1, 3, 6, and 12 months after the 
surgery, followed by yearly updates.  
The end points of the analysis of graft survival were repeat graft replacement for any reason, 
reoperation on the graft, or death of the patient with the graft in place. Long-term survival, 
freedom from recurrence of infection, reoperation, and cardiac death were assessed by 
Kaplan-Meier method using statistical analysis computer software, SAS ver. 5 (SAS Institute 
Inc., Cary NC, USA). Patients who survived more than 30 days after the procedure were 
included in the calculation for long-term analysis.  
4.2 Results 
A total of 60 patients received allograft transplantation during the observation period. 
Follow-up ranged from 2 days to 144.6 months (mean, 35.5 months). Mean age at time of 
operation was 52+/-16 years (range, 9 months – 74 years), and the majority of the patients 
were between 40 and 70 years of age. Most of the patients (48, 80%) were male. The majority 
of patients were diagnosed with active infective endocarditis (56/60, 93.3%) including 42 
prosthetic valve endocarditis (29 mechanical prostheses, 10 bioprosthetes, 2 homografts, and 
1 autograft), and 14 cases of native valve endocarditis. Forty-five cases (75%) presented with 
advanced infection with aortic annular abscess formation or extensive destruction of the 
aortic root structure. Microorganisms were isolated from 43 cases by preoperative blood 
culture, most of them being Staphylococcus.spp. or Streptococcus spp., and MRSA was isolated 
from 6 of the 43 cases (14.0%). All the cases received antibiotic regimen prior to the surgery, 
however, urgent decision making was required to decide on surgery in most cases because 
of their hemodynamic instability and arrhythmia resulting from sudden onset of valvular 
disorders (in most cases, acute regurgitation), large amounts of vegetation on the valve 
leaflets, and progression of prosthetic valve dehiscence from the annulus. Four cases 
received allografts for non-infective reason; 2 cases for aortic root pseudoaneurysm after 
aortic root replacement, 1 for prosthetic valve dehiscence from the annulus because of 
Behcet’s disease, and 1 for congenital aortic stenosis after balloon valvuloplasty. Fifty-four 
cases (90%) were the repeat surgery of the aortic root. Almost all cases were considered very 
high risk for surgical intervention (Figure 5 a,b).  
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Surgical techniques especially for proximal anastomosis at the aortic root have changed 
overtime; circumferential interrupted proximal suture technique in early days,  intermittent 
continuous suture anastomoses with 6 to 8 stitches in the next era, and interrupted suture at 
the posterior anastomosis line and intermittent continuous suture in the anterior side of the 
proximal anastomosis line recently. The method of coronary artery reconstruction was 
carried out by direct reimplantation of the coronary buttons or interposition between the 
coronary ostium and allograft wall using the aortic arch branches of the allografts especially 
in repeat cases (Figure 5c) [Ohtsuka et al, 2001]. Coronary artery bypass grafting was added, 
if necessary. Short-term outcome showed a 30-day operative mortality of 11.7% (7/60), and 
the causes of death were uncontrolled infection in 3 cases, low output syndrome in 2 cases, 
multisystem organ failure (MOF) in 1 case, and bleeding in 1 case. Long-term results 
showed that the 1-year, 5-year, and 10-year survival rates were 88%, 61% and 53%, 
respectively (Figure 6a). Freedom from recurrent infection was 94%, 91%, and 91%, 
respectively (Figure 6c), and freedom from reoperation rates were 92%, 69%, and 55%,  
 
  
                                      (a)                                                                            (b) 
 
                                                                              (c) 
Fig. 5. (a) Annular abscess at the aortic root; (b) Prosthetic valve is detatched from the 
annulus due to the infection; (c) Reconstruction of the aortic root with coronary artery 
reconstruction using a piece of arterial allograft 
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respectively (Figure 6d). The longest surviving graft has lasted 144.6 months. The causes of 
allograft loss were: uncontrolled infection in 4 cases, heart failure arising from aortic 
insufficiency in 3 cases, bleeding in 1 case, and MOF in 1 case.  The other 6 cases were lost 
due to non-cardiac reasons. The major indications for reoperation were pseudoaneurysm at 
the anastomosis sites (either proximal or distal anastomosis line), allograft aortic valve 
insufficiency due to perforation of the non-coronary cusp [Saito et al, 2003], and bleeding at 
the proximal anastomosis.  
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Fig. 6. (a) Cumulative survival after aortic root replacement with allograft (conditional 
survival); (b) Freedom from cardiac death; (c) Freedom from recurrence of infection;  
(d) Freedom from reoperation 
5. Conclusions 
The aortic root replacement with heart valve allograft was carried out successfully in 
patients with extensive infective lesions around the aortic root for whom the estimated 
operative mortality was very high. The allografts’ nature of anti-infection property was 
thought to be beneficial in those critical infective disease, and long-term prognosis was 
satisfactory once the infection was controlled by surgery. Pseudoaneurysm formation at the 
anastomosis line appeared to be the major issue to overcome in order to improve the 
operative outcome.  
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